Efficacy of Omadacycline or Vancomycin Combined With Germinants for Preventing Clostridioides difficile Relapse in a Murine Model
The Journal of Infectious Diseases · 2023
DOI: 10.1093/infdis/jiac324 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Infectious Diseases, 2023. Verfasst von Noah D Budi und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, University of Wisconsin-Madison, Madison, Wisconsin, USA. Hauptthemen laut MEDLINE: Clostridioides difficile, Clostridium Infections. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Paratek Pharmaceuticals.
Abstract (Originalsprache)
Background
Clostridioides difficile infections (CDI) and recurrence (rCDI) are major health care burdens. Recurrence is likely caused by spores in the gastrointestinal tract that germinate after antibiotic therapy. This murine study explores germinant-antibiotic combinations for CDI.
Methods
Previously described murine models were evaluated using C. difficile VPI 10463. The severe model compared omadacycline versus vancomycin in survival, weight loss, clinical scoring, and C. difficile toxin production. The nonsevere model compared these antibiotics with and without germinants (solution of sodium taurocholate, taurine, sodium docusate, calcium gluconate). Additionally, colon histopathology, bile acid analysis, environmental/spore shedding, and 16S sequencing was evaluated.
Results
In the severe model, omadacycline-treated mice had 60% survival versus 13.3% with vancomycin (hazard ratio [HR], 0.327; 95% confidence interval [CI],.126–.848; P = .015) along with decreased weight loss, and disease severity. In the nonsevere model, all mice survived with antibiotic-germinant treatment versus 60% antibiotics alone (HR, 0.109; 95% CI, .02–.410; P = .001). Omadacycline resulted in less changes in bile acids and microbiota composition. Germinant-treated mice showed no signs of rCDI, spore shedding, or significant toxin production at 15 days.
Conclusions
In murine models of CDI, omadacycline improved survival versus vancomycin. Germinant-antibiotic combinations were more effective at preventing rCDI compared to antibiotics alone without inducing toxin production.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, University of Wisconsin-Madison, Madison, Wisconsin, USA.
- Division of Infectious Diseases, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA.
- William S. Middleton Memorial Veterans Hospital, Madison, Wisconsin, USA.
- Center for Precision Medicine Research, Marshfield Clinic Research Institute, Marshfield, Wisconsin, USA.
ORCID-Profile: Noah D Budi, Warren E Rose
Förderung
- Paratek Pharmaceuticals
Zitieren
APA
Budi, N. D., Godfrey, J. J., Safdar, N., Shukla, S. K., & Rose, W. E. (2023). Efficacy of Omadacycline or Vancomycin Combined With Germinants for Preventing Clostridioides difficile Relapse in a Murine Model. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiac324
Vancouver
Budi ND, Godfrey JJ, Safdar N, Shukla SK, Rose WE. Efficacy of Omadacycline or Vancomycin Combined With Germinants for Preventing Clostridioides difficile Relapse in a Murine Model. The Journal of Infectious Diseases. 2023. doi:10.1093/infdis/jiac324
BibTeX
@article{Budi2023,
author = {Budi, Noah D and Godfrey, Jared J and Safdar, Nasia and Shukla, Sanjay K and Rose, Warren E},
title = {Efficacy of Omadacycline or Vancomycin Combined With Germinants for Preventing Clostridioides difficile Relapse in a Murine Model},
journal = {The Journal of Infectious Diseases},
year = {2023},
doi = {10.1093/infdis/jiac324}
}
EUVIMED